{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-102383","form_type":"8-K","ticker":"OFIX","cik":"0000884624","company_name":"Orthofix Medical Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.581063+00:00","generated_at":"2026-05-17T21:13:13.327309+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Orthofix Q2 net sales $203.1M (+2.3%); adj. EBITDA $20.6M; positive FCF; reaffirms FY25 guide","bullets":["Pro forma net sales (ex-M6) $200.7M, +3.5% constant currency; net loss $(14.1)M vs $(33.4)M prior year.","Non-GAAP pro forma adjusted EBITDA $20.6M (10.3% margin), up 24% YoY; six straight quarters of margin expansion.","Free cash flow positive $4.5M in Q2; cash, equivalents and restricted cash $68.7M.","U.S. Spine Fixation sales +5% (volume +7%); BGT Fracture +7%; U.S. Orthopedics +28%.","FY2025 guidance reaffirmed: pro forma net sales $808-816M, adj. EBITDA $82-86M, positive FCF."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-102383","json":"https://secwatch.observer/filing/0000950170-25-102383.json","markdown":"https://secwatch.observer/filing/0000950170-25-102383.md","text":"https://secwatch.observer/filing/0000950170-25-102383.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/884624/000095017025102383/0000950170-25-102383-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/884624/000095017025102383/ofix-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:13:13.327309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}